The Robert Carr Fund is a unique donor established through a dialogue between global and regional HIV networks and Governments and other donors. This led to the creation of a fund that recognises the



ViiV Europe was one of EuroNPUD’s pioneering donors that first supported the development of EuroNPUD. In 20223 ViiV Europe invested new funds in the development of EuroNPUD network capacity and the work of our women’s team.

Camurus is a Swedish science-led pharmaceutical company committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic diseases.


  • This includes Buividal, a version of long acting depot buprenorphine, which offers people with opioid dependence access to buprenorphine in a formulation that allows for a weekly or monthly depot injection reducing the need to attend drug services on a daily or regular basis supporting greater freedom and autonomy.  Camurus has supported the work of EuroNPUD Opioid Agonist Treatment (OAT) Literacy and Rights Project. In particular this has supported the development of EuroNPUD’s OAT Client Guide - “OAT We Are In It Together”. This is a tool for championing the literacy and rights of people on OAT. 

    Ethypharm and Indivior have both supported the activities of EuroNPUD Opioid Agonist Treatment (OAT) Literacy and Rights Project and we look forward to building our funding relationship with these donors. 

    EuroNPUD is often mistaken for having far greater resources than we actually have. This reflects our highly efficient use of resources and the underpinning activist model that maximises the impact of donor investment. However, such a model also relies heavily on activist commitment and EuroNPUD invites other donors to join in supporting our work.